Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy

BACKGROUND: Lenvatinib monotherapy and combination therapy with immune checkpoint inhibitors (ICI) were widely applied for unresectable hepatocellular carcinoma (uHCC). However, many patients failed to benefit from the treatments. A prognostic model was needed to predict the treatment outcomes and g...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, De-Zhen, Zhang, Shi-Yu, Dong, San-Yuan, Yan, Jia-Yan, Wang, Yu-Peng, Cao, Ya, Rao, Sheng-Xiang, Fan, Jia, Yang, Xin-Rong, Huang, Ao, Zhou, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995378/
https://www.ncbi.nlm.nih.gov/pubmed/36911686
http://dx.doi.org/10.3389/fimmu.2023.1141199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995378/
https://www.ncbi.nlm.nih.gov/pubmed/36911686
http://dx.doi.org/10.3389/fimmu.2023.1141199

Ejemplares similares